{"organizations": [], "uuid": "4936a72cc2428f57e822710c2857c73313c23261", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 7}, "facebook": {"likes": 36, "shares": 36, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/img/WSJ_Logo_black_social.gif", "site_section": "https://www.wsj.com/europe", "section_title": "The Wall Street Journal &amp; Breaking News, Business, Financial and Economic News, World News and Video", "url": "https://www.wsj.com/articles/axovant-will-no-longer-develop-lead-dementia-drug-1515430108", "country": "US", "domain_rank": 387, "title": "Axovant Will No Longer Develop Lead Dementia Drug", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-01-08T19:48:00.000+02:00", "replies_count": 0, "uuid": "4936a72cc2428f57e822710c2857c73313c23261"}, "author": "Allison Prang", "url": "https://www.wsj.com/articles/axovant-will-no-longer-develop-lead-dementia-drug-1515430108", "ord_in_thread": 0, "title": "Axovant Will No Longer Develop Lead Dementia Drug", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Axovant Sciences Ltd. lost half of its market value Monday after it said a drug once intended to treat Alzheimer’s disease didn’t meet certain goals in recent studies.\nSwitzerland-based Axovant, whose shares fell 50% to $2.71 in morning trading, said it would no longer develop its main drug, known as intepirdine, that analysts once thought could top $2 billion in annual sales.\n“Based... ", "external_links": [], "published": "2018-01-08T19:48:00.000+02:00", "crawled": "2018-01-09T09:42:15.817+02:00", "highlightTitle": ""}